Filing summary
Registrant and period: The supplied filing is GSI Group Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 6, 2015. It does not identify Novanta Inc. as the registrant; verify the company match. The 10-K includes fourth-quarter results but reports principally on the full fiscal year.
Business context and reporting period
GSI designed and manufactured precision photonics, laser, medical technology, and motion-control components and subsystems, primarily for OEMs in medical and advanced industrial markets. It reported three segments: Laser Products, Medical Technologies, and Precision Motion. Approximately 61% of 2014 sales were outside the United States; no customer represented more than 10% of sales.
Financial performance
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $364.7 million | $316.9 million |
| Gross profit / margin | $150.2 million / 41.2% | $132.2 million / 41.7% |
| Operating income (loss), continuing operations | $(16.8) million | $19.4 million |
| Net income (loss) attributable to GSI | $(24.3) million | $7.3 million |
| Diluted EPS, continuing operations | $(0.49) | $0.29 |
| Cash from continuing operating activities | $44.0 million | $56.2 million |
| Cash and cash equivalents at year-end | $51.1 million | $61.0 million |
| Total debt at year-end | $115.0 million | $71.5 million |
Reported revenue rose 15.1%, but JADAK contributed $45.4 million of the increase; excluding JADAK and currency effects, organic growth was 0.7%. Segment revenue was $177.7 million for Laser Products, $122.2 million for Medical Technologies, and $64.8 million for Precision Motion. Segment operating income (loss) was $33.1 million, $(43.1) million, and $13.0 million, respectively.
Operating cash flow declined from 2013, in part because 2013 included $11.8 million of net tax refunds. Continuing-operations investing cash outflow was $93.5 million, mainly reflecting the $93.7 million JADAK purchase, partly offset by the NDS escrow recovery. Financing cash flow was $40.3 million. The company had $95.0 million available on its revolving facility at year-end. Its leverage ratio was 2.07 against a 3.00 maximum; fixed-charge coverage was 3.59 against a 1.50 minimum.
Material changes versus the prior period
- Revenue increased, largely due to the March 2014 JADAK acquisition; organic growth was modest.
- Gross margin edged down 0.5 percentage point. Precision Motion margin fell to 43.7% from 46.3%, attributed to manufacturing ramp-up costs; Laser Products margin improved to 41.8% from 41.3%.
- Operating results turned to a loss, principally due to a $41.4 million non-cash impairment of NDS goodwill and intangible assets. Management said the impairment did not affect cash flow, liquidity, or debt-covenant compliance.
- Medical Technologies revenue included JADAK, but visualization sales weakened amid OEM dual sourcing, softer medical-equipment spending, and delayed product launches. NDS expectations were lowered after weaker-than-expected demand and a decision to discontinue certain products.
- Debt increased to fund acquisitions. GSI received $5.4 million from an NDS escrow claim and sold Scientific Lasers in July 2014 for $6.5 million net of working-capital adjustments, recording a $1.7 million disposal loss.
Outlook, risks, and unusual items
- No specific revenue, earnings, or margin guidance is provided. Management stated that it expected operating cash flows to cover operating and capital expenditure needs for at least the next 12 months; this is subject to business and market risks.
- In February 2015, GSI acquired Applimotion for $13.9 million in cash, funded with cash and revolving borrowings. Management expected it to broaden precision-motion offerings.
- Key risks include cyclical OEM capital spending, customer order timing and cancellations, competition and pricing pressure, product-development and integration execution, reliance on some single-source suppliers, international and foreign-exchange exposure, and medical-device and other regulatory requirements.
- Debt was variable-rate; management estimated that a 100-basis-point rate increase would add about $1.2 million to annual pretax interest expense. The company held no foreign-currency or interest-rate derivative contracts at year-end.
- Other notable items include discontinued-operations losses and a tax benefit of $1.0 million despite a pretax loss, affected by valuation allowances and the geographic allocation of the NDS impairment. The company reported no material off-balance-sheet arrangements and no legal proceedings it believed would materially affect results.
- The independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting. JADAK, representing 7% of year-end assets and 12% of 2014 continuing revenue, was excluded from the internal-control assessment because it was acquired during the year.
Important facts for investors to verify
- Confirm that this GSI Group Inc. 2014 10-K is the intended filing for the requested company, Novanta Inc.
- Review the assumptions behind the $41.4 million NDS impairment and whether the reduced sales and profit expectations persist.
- Assess underlying organic growth and segment trends separately from acquisition-driven revenue, particularly in Medical Technologies.
- Check debt repayment, revolving-facility usage, covenant headroom, and funding for the subsequent Applimotion acquisition.
- Evaluate the cash-flow outlook, working-capital needs, pension funding exposure, tax valuation allowances, and remaining discontinued-business obligations.